Therapy Areas: Inflammatory Diseases
Trellus Health renews licensing agreement with Pfizer
13 April 2026 - Healthcare company Trellus Health plc (AIM: TRLS) announced on Monday that it has renewed its licensing agreement with biopharmaceutical company Pfizer Inc, extending the use of its pa...
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
13 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced on Monday that they have rece...
GSK secures China approval for Exdensur to treat nasal polyp condition
8 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has received approval from China's National Medical Products Administration for Exdensur (dep...
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
8 April 2026 - Biopharmaceutical company Insmed Incorporated (Nasdaq:INSM) disclosed on Tuesday that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hid...
Alloy Therapeutics and Biogen expand partnership with multi-target antisense collaboration
7 April 2026 - Biotechnology ecosystem company Alloy Therapeutics announced on Tuesday that it has entered into a multi-target collaboration and licence agreement with biotechnology company Biogen Inc...
Parnell launches first FDA-approved generic florfenicol and flunixin combination for bovine respiratory disease
1 April 2026 - Veterinary pharmaceutical company Parnell Technologies Pty Ltd on Wednesday announced the US launch of nixiFLOR, an injectable solution approved by the US Food and Drug Administration (...